Immunotherapy News and Research

Latest Immunotherapy News and Research

Novel platform allowing universal off-the-shelf T and NK cell access shows potential for immunotherapies

Recent advances in immunotherapy for cancer have stimulated a plethora of studies aimed at developing T cells (white blood cells) and Natural Killer (NK) cells (immune cells with enzymes that can kill tumor cells or cells infected with a virus) in-vitro from pluripotent stem cells - cells that are able to self-renew by dividing and developing into the three primary groups of cells that make up a human body.

3 Nov 2022

Study explores the potential use of anti-thymic stromal lymphopoietin monoclonal antibody as an adjuvant in allergic immunotherapy

A new study investigated the impact of a monoclonal anti-thymic stromal lymphopoietin (TSLP) antibody on subcutaneous allergen immunotherapy (SCIT) efficacy among patients with allergic rhinitis.

3 Nov 2022

Vaccination with senescent cells could be a possible therapy against cancer

Cancer cells have a series of features that allow the immune system to identify and attack them. However, these same cells create an environment that blocks immune cells and protects the tumor.

3 Nov 2022

Targeted therapy for children with high-risk Hodgkin lymphoma reduces relapse rates, trial shows

A targeted therapy for children with high-risk Hodgkin lymphoma (HL) was shown to significantly reduce relapse rates when tested in a large multicenter clinical trial conducted by the Children's Oncology Group (COG) and led by pediatric oncologists at Roswell Park Comprehensive Cancer Center, Children's Healthcare of Atlanta and Winship Cancer Institute of Emory University. By combining the targeted antibody-drug conjugate (ADC) brentuximab vedotin (BV) with the standard chemotherapy regimen, children were 10% less likely to relapse.

2 Nov 2022

Researchers find the root of immunosuppression and chemoresistance in TNBC tumors

Triple-negative breast cancer (TNBC) tumors gain immunosuppression and chemoresistance through interactions between interleukin 34 and myeloid-derived suppressor cells, researchers find.

1 Nov 2022

New nanovaccine greatly improves cytokine production

Cancer immunotherapies, such as immune checkpoint inhibition therapy, have been attracting attention in recent years as new methods for treating cancer. However, immune checkpoint inhibition therapy is only effective in 20%–30% of cancer patients, so developing better drug delivery systems to induce anticancer cellular immunity is necessary.

1 Nov 2022

BCRF renews funding to support the development of novel therapeutics for triple-negative breast cancer

The Breast Cancer Research Foundation (BCRF) has renewed its funding to Elisa Port, MD, and Hanna Irie, MD, PhD, to study new therapeutic approaches that target aggressive triple-negative breast cancer.

31 Oct 2022

Artificial intelligence-based method may help predict early-stage melanoma recurrence

Most deaths from melanoma - the most lethal form of skin cancer - occur in patients who were initially diagnosed with early-stage melanoma and then later experienced a recurrence that is typically not detected until it has spread or metastasized.

31 Oct 2022

Cleveland Clinic awarded $12 million NIH grant to define how cytokines regulate inflammation

Cleveland Clinic's Lerner Research Institute was awarded a five-year $12 million grant by the National Cancer Institute, part of the National Institutes of Health, to define how cytokines - proteins produced during immune response - regulate inflammation and interact with cells and molecules surrounding tumors.

28 Oct 2022

Novel nanotechnology triggers potent therapeutic anti-tumor immune responses against multiple cancers

A Ludwig Cancer Research study has developed a novel nanotechnology that triggers potent therapeutic anti-tumor immune responses and demonstrated its efficacy in mouse models of multiple cancers.

28 Oct 2022

Research reveals a differential clinical response to pembrolizumab in uterine cancer patients

New research from Yale Cancer Center reveals for the first time ever a differential clinical response to pembrolizumab in Lynch-like (mutated) vs methylated microsatellite instability-high (MSI-H) uterine cancer patients, increasing our understanding about the proportion of patients that derive benefit from immune checkpoint blockade.

28 Oct 2022

Study sheds light on why some patients respond better than others to immunotherapy

Immunotherapy, a biotherapy that boosts the ability of the immune system to recognize and attack mutant tumor cells, has transformed the treatment landscape for patients battling cancer, which emerges from the progressive accumulation of DNA mutations.

27 Oct 2022

Advanced type of nanoparticle could help fight hard-to-treat cancers

Nanoparticles, or tiny molecules that can deliver a payload of drug treatments and other agents, show great promise for treating cancers.

27 Oct 2022

Metabolite product from pomegranate improves the function of immune cells to fight against cancer

As part of an interdisciplinary project of the LOEWE Centre Frankfurt Cancer Institute (FCI), researchers from the Georg-Speyer-Haus in Frankfurt am Main, Germany, and Goethe University Frankfurt have succeeded in identifying a new approach for the therapy of colorectal cancer.

27 Oct 2022

Exploring new therapeutic targets and biomarkers for neurodegenerative disorders

In this interview, Dr. Shebna Massey discusses neurodegenerative diseases such as Alzheimer's, Parkinson's, Huntington's, and more. She also discusses and explores new therapeutic targets and biomarkers for these diseases.

From Sino Biological Inc. 26 Oct 2022

Discovery of small molecule enzyme inhibitor could be the key to treating cancers, autoimmune diseases

Researchers at the University of Illinois Chicago have found a small molecule capable of manipulating an immune process that plays an important role in cancers and autoimmune diseases.

25 Oct 2022

New approach to immunotherapy provokes a robust anti-tumor immune response in preclinical models

A new approach to cancer immunotherapy that uses one type of immune cell to kill another - rather than directly attacking the cancer - provokes a robust anti-tumor immune response that shrinks ovarian, lung, and pancreatic tumors in preclinical disease models, according to researchers at the Icahn School of Medicine at Mount Sinai in New York.

25 Oct 2022

Researchers streamline way to manufacture CAR T-cells in just 24 hours

Researchers at University Hospitals (UH) Seidman Cancer Center and a biotech start-up company have developed a streamlined way to manufacture CAR T-cells for immunotherapy treatment in just 24 hours – an improvement over the team's previous benchmark of eight days and commercial suppliers that typically take three weeks.

25 Oct 2022

Combination of radiation and systemic therapy can prolong survival for advanced liver cancer patients

Adding radiation therapy to systemic therapy for patients with advanced liver cancer can extend overall survival and delay tumor progression without compromising patients' quality of life, a randomized phase III clinical trial shows.

24 Oct 2022

Breakthrough discovery is a 'major step forward' in understanding cervical cancer

Scientists have discovered that cervical cancer can be divided into two distinct molecular subgroups – one far more aggressive than the other – as part of the largest 'omics' study of its kind, led by researchers at UCL and the University of Southampton.

21 Oct 2022

Immunotherapy News and Research

Latest Immunotherapy News and Research

Novel platform allowing universal off-the-shelf T and NK cell access shows potential for immunotherapies

Study explores the potential use of anti-thymic stromal lymphopoietin monoclonal antibody as an adjuvant in allergic immunotherapy

Vaccination with senescent cells could be a possible therapy against cancer

Targeted therapy for children with high-risk Hodgkin lymphoma reduces relapse rates, trial shows

Researchers find the root of immunosuppression and chemoresistance in TNBC tumors

New nanovaccine greatly improves cytokine production

BCRF renews funding to support the development of novel therapeutics for triple-negative breast cancer

Artificial intelligence-based method may help predict early-stage melanoma recurrence

Cleveland Clinic awarded $12 million NIH grant to define how cytokines regulate inflammation

Novel nanotechnology triggers potent therapeutic anti-tumor immune responses against multiple cancers

Research reveals a differential clinical response to pembrolizumab in uterine cancer patients

Study sheds light on why some patients respond better than others to immunotherapy

Advanced type of nanoparticle could help fight hard-to-treat cancers

Metabolite product from pomegranate improves the function of immune cells to fight against cancer

Exploring new therapeutic targets and biomarkers for neurodegenerative disorders

Discovery of small molecule enzyme inhibitor could be the key to treating cancers, autoimmune diseases

New approach to immunotherapy provokes a robust anti-tumor immune response in preclinical models

Researchers streamline way to manufacture CAR T-cells in just 24 hours

Combination of radiation and systemic therapy can prolong survival for advanced liver cancer patients

Breakthrough discovery is a 'major step forward' in understanding cervical cancer

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Immunotherapy News and Research

Latest Immunotherapy News and Research

eBook: Cell-based technologies in drug discovery and Immunotherapy eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in